Loading...
Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Lenalidomide is an oral immunomodulatory agent approved in relapsed multiple myeloma with dexamethasone, for transfusion-dependent anemia in myelodysplastic syndrome associated with deletion 5q, and in relapsed/progressive mantle cell lymphoma following bortezomib. In recent clinical trials, lenalid...
Na minha lista:
| Udgivet i: | J Adv Pract Oncol |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Harborside Press
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4457182/ https://ncbi.nlm.nih.gov/pubmed/26110071 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|